Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
American Journal of Preventive Cardiology
|
December 17, 2024
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
Gregory P Geba, Ruifeng Chen, Kasturi Talapatra, et al.
Arthritis and Rheumatism
|
February 12, 2004
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial
Bernard R Rubin, Robert Burton, Sandra Navarra, et al.
The Journal of Allergy and Clinical Immunology
|
June 2, 2010
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma
William W Busse, Rohit Katial, David Gossage, et al.
Scientific Reports
|
August 7, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Dateng Li, Meng Xu, Andrea T Hooper, et al.
Immunology
|
September 24, 2004
Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma
Ivana Kawikova, Vipin Paliwal, Marian Szczepanik, et al.
Mbio
|
October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Journal of the American Geriatrics Society
|
April 17, 2004
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
Alan J Kivitz, Maria W Greenwald, Stanley B Cohen, et al.
Journal of the American Heart Association
|
August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Gregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
Osteoarthritis and Cartilage Open
|
November 18, 2024
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip
Stephen J DiMartino, Jingning Mei, Thomas J Schnitzer, et al.
BMC Musculoskeletal Disorders
|
February 25, 2025
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip
Stephen J DiMartino, Haitao Gao, Simon Eng, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
American Journal of Preventive Cardiology
|
December 17, 2024
Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
Gregory P Geba, Ruifeng Chen, Kasturi Talapatra, et al.
Arthritis and Rheumatism
|
February 12, 2004
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial
Bernard R Rubin, Robert Burton, Sandra Navarra, et al.
The Journal of Allergy and Clinical Immunology
|
June 2, 2010
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma
William W Busse, Rohit Katial, David Gossage, et al.
Scientific Reports
|
August 7, 2023
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
Dateng Li, Meng Xu, Andrea T Hooper, et al.
Immunology
|
September 24, 2004
Airway hyper-reactivity mediated by B-1 cell immunoglobulin M antibody generating complement C5a at 1 day post-immunization in a murine hapten model of non-atopic asthma
Ivana Kawikova, Vipin Paliwal, Marian Szczepanik, et al.
Mbio
|
October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Journal of the American Geriatrics Society
|
April 17, 2004
Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
Alan J Kivitz, Maria W Greenwald, Stanley B Cohen, et al.
Journal of the American Heart Association
|
August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Gregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
Osteoarthritis and Cartilage Open
|
November 18, 2024
A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip
Stephen J DiMartino, Jingning Mei, Thomas J Schnitzer, et al.
BMC Musculoskeletal Disorders
|
February 25, 2025
Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip
Stephen J DiMartino, Haitao Gao, Simon Eng, et al.
Page
of 7